Home Applications 012928 Application 012928
Type NDA
Sponsor LILLY Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 002 NOVRAD LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS SUSPENSION;ORAL EQ 50MG BASE/5ML No No 004 NOVRAD LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS CAPSULE;ORAL EQ 100MG BASE No No 006 NOVRAD LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS CAPSULE;ORAL EQ 50MG BASE No No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N012928-002 NOVRAD LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS EQ 50MG BASE/5ML SUSPENSION / ORAL Approved before 1982 N012928-004 NOVRAD LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS EQ 100MG BASE CAPSULE / ORAL Approved before 1982 N012928-006 NOVRAD LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS EQ 50MG BASE CAPSULE / ORAL Approved before 1982
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 4 of 4 · 132 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N012928-002 NOVRAD EQ 50MG BASE/5ML SUSPENSION / ORAL Approved before 1982 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N012928-004 NOVRAD EQ 100MG BASE CAPSULE / ORAL Approved before 1982 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N012928-006 NOVRAD EQ 50MG BASE CAPSULE / ORAL Approved before 1982 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N012928-002 NOVRAD EQ 50MG BASE/5ML SUSPENSION / ORAL Approved before 1982 e64feba35796…2022-09-29 23:25 UTC 2022-09 N012928-004 NOVRAD EQ 100MG BASE CAPSULE / ORAL Approved before 1982 e64feba35796…2022-09-29 23:25 UTC 2022-09 N012928-006 NOVRAD EQ 50MG BASE CAPSULE / ORAL Approved before 1982 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N012928-002 NOVRAD EQ 50MG BASE/5ML SUSPENSION / ORAL Approved before 1982 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N012928-004 NOVRAD EQ 100MG BASE CAPSULE / ORAL Approved before 1982 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N012928-006 NOVRAD EQ 50MG BASE CAPSULE / ORAL Approved before 1982 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N012928-002 NOVRAD EQ 50MG BASE/5ML SUSPENSION / ORAL Approved before 1982 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N012928-004 NOVRAD EQ 100MG BASE CAPSULE / ORAL Approved before 1982 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N012928-006 NOVRAD EQ 50MG BASE CAPSULE / ORAL Approved before 1982 a50c72e98297…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.